Johnson & Johnson's Janssen Pharmaceutical Highlights Presentation Of Imbruvica Long-Term Data From Two Pivotal Phase 3 Studies At ASCO And EHA Demonstrating Sustained Efficacy And Safety In Patients With Chronic Lymphocytic Leukemia